wkymvm

WKYMVM is a N-formyl peptide receptor (FPR1) agonist.

WKYMVm is a selective FPR2 agonist with high affinity, which was identified through screening of a synthetic peptide library.

WKYMVM-NH2 TFA, a potent agonist for N-formyl peptide receptor (FPR1) and FPRL1/2, activates key leukocyte effector functions including chemotaxis, complement receptor-3 mobilization, and NADPH oxidase activation, as documented in references [1] [2] [3].

WRW4 TFA (878557-55-2 free base) is a specific formyl peptide receptor-like 1 (FPRL1) antagonist, inhibits WKYMVm binding to FPRL1 with an IC50 of 0.23 μM. WRW4 TFA(878557-55-2 free base) specifically inhibits the increase in intracellular calcium by the FPRL1 agonists MMK-1, amyloid beta42 (Abeta42) peptide, and F peptide.

WRW4 TFA is a formyl peptide receptor-like 1 (FPRL1) antagonist that specifically prevents the binding of WKYMVm to FPRL1 with an inhibition concentration (IC50) of 0.23 μM. It uniquely blocks the rise in intracellular calcium triggered by FPRL1 agonists such as MMK-1, amyloid beta42 (Abeta42) peptide, and F peptide [1].

WRW4-OH is a bioactive peptide that impedes the interaction of the FPRL1 agonist WKYMVm with its designated receptor. As a classical chemoattractant receptor prevalent in phagocytic cells of peripheral blood and brain, FPRL1's activation is integral to inflammatory responses within host defense mechanisms and is implicated in neurodegenerative disorders.